Increased serum levels of chromogranin A in male smokers with airway obstruction

European Respiratory Journal

Volumn 28, Issue 3, 2006, Pages 542-548

  Sørhaug, Sveinung ^a,b   Langhammer, A ^a   Waldum, H L ^a,b   Hveem, K ^a   Steinshamn, S ^a,b  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

Airway obstruction; Chromogranin A; Lung function; Neuroendocrine system; Sex; Smoking

Indexed keywords

CHROMOGRANIN A;

AIRWAY OBSTRUCTION; ARTICLE; BLOOD SAMPLING; CHRONIC BRONCHITIS; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE LINEAR REGRESSION ANALYSIS; NEUROENDOCRINE SYSTEM; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SMOKING HABIT; SPIROMETRY; SYMPTOM;

ADULT; AIRWAY OBSTRUCTION; CHROMOGRANIN A; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROSECRETORY SYSTEMS; SMOKING;

EID: 33751304132     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.06.00092205     Document Type: Article

References (39)

1. Aguayo SM. Neuroendocrine cells and airway wall remodelling in chronic airflow obstruction: a perspective. Monaldi Arch Chest Dis 1994; 275: 243-248.
2. Cutz E, Jackson A. Neuroepithelial bodies as airway oxygen sensors. Respir Physiol 1999; 115: 201-214.
3. Van Lommel A. Pulmonary neuroendocrine cells (PNEC) and neuroepithelial bodies (NEB): chemoreceptors and regulators of lung development. Paediatr Respir Rev 2001; 2: 171-176.
4. Carney DN, Cuttitta F, Moody TW, Minna JD. Selective stimulation of small cell lung cancer clonal growth by bombesin and gastrin-releasing peptide. Cancer Res 1987; 47: 821-825.
5. Aguayo SM. Determinants of susceptibility to cigarette smoke. Potential roles for neuroendocrine cells and neuropeptides in airway inflammation, airway wall remodeling, and chronic airflow obstruction. Am J Respir Crit Care Med 1994; 149: 1692-1698.
6. Gosney JR, Sissons MC, Allibone RO, Blakey AF. Pulmonary endocrine cells in chronic bronchitis and emphysema. J Pathol 1989; 157: 127-133.
7. Chen MF, Diotallevi MJ, Kimizuka G, King M, Wang NS. Nicotine-induced neuroepithelial cell changes in young rabbits: a preliminary communication. Pediatr Pulmonol 1985; 1: 303-308.
8. Tabassian AR, Nylen ES, Linnoila RI, Snider RH, Cassidy MM, Becker KL. Stimulation of hamster pulmonary neuroendocrine cells and associated peptides by repeated exposure to cigarette smoke. Am Rev Respir Dis 1989; 140: 436-440.
9. Van Lommel A, Bolle T, Fannes W, Lauweryns JM. The pulmonary neuroendocrine system: the past decade. Arch Histol Cytol 1999; 62: 1-16.
10. Adriaensen D, Timmermans JP. Purinergic signalling in the lung: important in asthma and COPD? Curr Opin Pharmacol 2004; 4: 207-214.
11. Nobels FR, Kwekkeboom DJ, Bouillon R, Lamberts SW. Chromogranin A: its clinical value as marker of neuroendocrine tumours. Eur J Clin Invest 1998; 28: 431-440.
12. Taupenot L, Harper KL, O'Connor DT. The chromogranin-secretogranin family. N Engl J Med 2003; 348: 1134-1149.
13. Langhammer A, Johnsen R, Gulsvik A, Holmen TL, Bjermer L. Sex differences in lung vulnerability to tobacco smoking. Eur Respir J 2003; 21: 1017-1023.
14. Sanduleanu S, De Bruine A, Stridsberg M, et al. Serum chromogranin A as a screening test for gastric enterochromaffin-like cell hyperplasia during acid-suppressive therapy. Eur J Clin Invest 2001; 31: 802-811.
15. American Thoracic Society, Standardization of Spirometry, 1994 Update. American Thoracic Society. Am J Respir Crit Care Med 1995; 152: 1107-1136.
16. Langhammer A, Johnsen R, Gulsvik A, Holmen TL, Bjermer L. Forced spirometry reference values for Norwegian adults: the Bronchial Obstruction in Nord-Trondelag Study. Eur Respir J 2001; 18: 770-779.
17. National Heart, Lung and Blood Institute & World Health Organisation. Global Initiative for Chronic Obstructive Lung Disease. 2004. www.goldcopd.com/Guidelineitem.asp?l1=2&12=1&intld=996 Date last updated: September 2005.
18. Stridsberg M, Oberg K, Li Q, Engstrom U, Lundqvist G. Measurements of chromogranin A, chromogranin B (secretogranin I), chromogranin C (secretogranin II) and pancreastatin in plasma and urine from patients with carcinoid tumours and endocrine pancreatic tumours. J Endocrinol 1995; 144: 49-59.
19. Syversen U, Ramstad H, Gamme K, Qvigstad G, Falkmer S, Waldum HL. Clinical significance of elevated serum chromogranin A levels. Scand J Gastroenterol 2004; 39: 969-973.
20. Hsiao RJ, Neumann HP, Parmer RJ, Barbosa JA, O'Connor DT. Chromogranin A in familial pheochromocytoma: diagnostic screening value, prediction of tumor mass, and post-resection kinetics indicating two-compartment distribution. Am J Med 1990; 88: 607-613.
21. Aardal S, Helle KB. The vasoinhibitory activity of bovine chromogranin A fragment (vasostatin) and its independence of extracellular calcium in isolated segments of human blood vessels. Regul Pept 1992; 41: 9-18.
22. Ratti S, Curnis F, Longhi R, et al. Structure-activity relationships of chromogranin A in cell adhesion. Identification of an adhesion site for fibroblasts and smooth muscle cells. J Biol Chem 2000; 275: 29257-29263.
23. Gasparri A, Sidoli A, Sanchez LP, et al. Chromogranin A fragments modulate cell adhesion. Identification and characterization of a pro-adhesive domain. J Biol Chem 1997; 272: 20835-20843.
24. Mahata SK, O'Connor DT, Mahata M, et al. Novel autocrine feedback control of catecholamine release. A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist. J Clin Invest 1997; 100: 1623-1633.
25. Lugardon K, Raffner R, Goumon Y, et al. Antibacterial and antifungal activities of vasostatin-1, the N-terminal fragment of chromogranin A. J Biol Chem 2000; 275: 10745-10753.
26. Aguayo SM, Kane MA, King Jr TE, Schwarz MI, Grauer L, Miller YE. Increased levels of bombesin-like peptides in the lower respiratory tract of asymptomatic cigarette smokers. J Clin Invest 1988; 43: 1105-1113.
27. Wouters EF. Chronic obstructive pulmonary disease. 5. Systemic effects of COPD. Thorax 2002; 57: 1067-1070.
28. Andreas S, Anker SD, Scanlon PD, Somers VK. Neurohumoral activation as a link to systemic manifestations of chronic lung disease. Chest 2005; 128: 3618-3624.
29. Ceconi C, Ferrari R, Bachetti T, et al. Chromogranin A in heart failure; a novel neurohumoral factor and a predictor for mortality. Eur Heart J 2002; 23: 967-974.
30. Omland T, Dickstein K, Syversen U. Association between plasma chromogranin A concentration and long-term mortality after myocardial infarction. Am J Med 2003; 114: 25-30.
31. Schuller HM, Jull BA, Sheppard BJ, Plummer HK. Interaction of tobacco-specific toxicants with the neuronal alpha(7) nicotinic acetylcholine receptor and its associated mitogenic signal transduction pathway: potential role in lung carcinogenesis and pediatric lung disorders. Eur J Pharmacol 2000; 393: 265-277.
32. Waldum HL, Nilsen OG, Nilsen T, et al. Long-term effects of inhaled nicotine. Life Sci 1994; 49: 1339-1346.
33. Meloni F, Ballabio P, Pistorio A, et al. Urinary levels of bombesin-related peptides in a population sample from northern Italy: potential role in the pathogenesis of chronic obstructive pulmonary disease. Am J Med Sci 1998; 315: 258-265.
34. Takiyyuddin MA, Neumann HP, Cervenka JH, et al. Ultradian variations of chromogranin A in humans. Am J Physiol 1991; 261: R939-R944.
35. Tsao KC, Wu JT. Development of an ELISA for the detection of serum chromogranin A (CgA) in prostate and non-neuroendocrine carcinomas. Clin Chim Acta 2001; 313: 21-29.
36. Nobels FR, Kwekkeboom DJ, Coopmans W, et al. A comparison between the diagnostic value of gonadotropins, alpha-subunit, and chromogranin-A and their response to thyrotropin-releasing hormone in clinically nonfunctioning, alpha-subunit-secreting, and gonadotroph pituitary adenomas. J Clin Endocrinol Metab 1993; 77: 784-789.
37. O'Connor DT, Pandlan MR, Carlton E, Cervenka JH, Hslao RJ. Rapid radioimmunoassay of circulating chromogranin A: in vitro stability, exploration of the neuroendocrine character of neoplasia, and assessment of the effects of organ failure. Clin Chem 1989; 35: 1631-1637.
38. Giampaolo B, Angelica M, Antonio S. Chromogranin "A" in normal subjects, essential hypertensives and adrenalectomized patients. Clin Endocrinol 2002; 57: 41-50.
39. Waldum HL, Syversen U. Serum chromogranin A in the control of patients on long-term treatment with inhibitors of acid secretion. Eur J Clin Invest 2001; 31: 741-743.